| Title : Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods - Henstra_2022_Front.Psychiatry_13_953686 |
| Author(s) :
Henstra MJ , Feenstra TC , Kok RM , Spaans HP , van Exel E , Dols A , Oudega M , Vergouwen ACM , van der Loo A , Bet PM , Loer SA , Eikelenboom M , Sienaert P , Lambrichts S , Bouckaert F , Bosmans JE , van der Velde N , Beekman ATF , Stek ML , Rhebergen D |
|
Ref :
Front Psychiatry , 13 :953686 , 2022 |
| Abstract : Henstra_2022_Front.Psychiatry_13_953686 |
| ESTHER : Henstra_2022_Front.Psychiatry_13_953686 |
| PubMedSearch : Henstra_2022_Front.Psychiatry_13_953686 |
| PubMedID: 35911242 |